---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000238"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:00:36.935519+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Charles River Q4 2023 revenue down 7.9% to $1.01B; non-GAAP EPS $2.46; 2024 guidance organic growth 0-3%

## Summary
- Q4 GAAP EPS $3.62 vs $3.65 YoY; non-GAAP EPS $2.46 vs $2.98, down 17.4%.
- Full-year 2023 revenue $4.13B (+3.9%); GAAP EPS $9.22; non-GAAP EPS $10.67.
- 2024 guidance: organic revenue growth 0%-3%; GAAP EPS $7.90-$8.40; non-GAAP EPS $10.90-$11.40.
- Noveprim acquisition completed Nov 2023 (additional 41% stake for $144.6M, now 90% controlling interest).
- DSA segment revenue fell 9.5% in Q4; Manufacturing organic growth +2.3% but revenue down 9.5%.

## SEC filing metadata
- accession: 0001157523-24-000238
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/a53896037.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000238
- JSON: https://secwatch.observer/filing/0001157523-24-000238.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000238.txt

## Key facts
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fourth quarter ended December 30, 2023 results: revenue $1.01 billion, net income $187.1 million, EPS $3.62 per share.
  - Period: the fourth quarter ended December 30, 2023
  - Revenue: $1.01 billion
  - Net income: $187.1 million
  - EPS: $3.62 per share
  - Result: reported results
  source text: EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. updated its 2024 guidance (initiated).
  - Period: 2024
  - Guidance: initiated
  - Result: guidance update
  source text: Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fiscal year ended December 30, 2023 results: revenue $4.13 billion, EPS $9.22 per share.
  - Period: the fiscal year ended December 30, 2023
  - Revenue: $4.13 billion
  - EPS: $9.22 per share
  - Result: reported results
  source text: Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 Guidance –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.